US business full-year growth of 10-12%
Management expects US business to grow 10-12% for the full year FY26, driven by volume growth and new launches.
APLLTD / guidance tracker
Keep management guidance in view.
Alembic Pharmaceuticals · forward-looking guidance across the available source record.
Research layer active
Guidance tracker
What management said would happen.
revenue
India branded business to align with market growth by Q1 FY27
Management expects India branded business growth to converge with the market growth rate by Q1 of the next financial year.
R&D spend of ₹600-650 crore for FY26
Full-year R&D spend guidance of ₹600-650 crore, representing 8-9% of revenue.
Pivya launch in Q4 FY26
First branded product Pivya to be launched in the US in Q4 FY26, with prescription share scaling over 12-18 months.
Low double-digit consolidated revenue growth in FY27
Management targets low double-digit topline growth for FY27 at consolidated level.
R&D spend of ₹750-800 crore in FY27
R&D investments expected to be around ₹750-800 crore, focusing on complex and peptide developments.
Capex of ₹300-350 crore in FY27
Capital expenditure guided at ₹300-350 crore, primarily for capacity debottlenecking and replacement.
US branded business to scale meaningfully in next few quarters
With Pivya launch, branded franchise expected to reach meaningful revenue profile in next few quarters.